Table 4.
Treatment post osimertinib
| Additional lines of treatment, n (%) | |
| 0 | 12 (52.2) |
| 1 | 6 (26.1) |
| 2 | 1 (4.3) |
| 3 | 4 (17.4) |
| Type of treatment, n (%) | |
| Chemotherapy | 8 (72.7) |
| Immunotherapy | 3 (27.3) |
| EGFR TKI | 3 (27.3) |
| Radiotherapy | 3 (27.3) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.